文献速递贫血与红细胞疾病

中国免疫性血小板减少症患者感染COVID-19的特征与结局:一项前瞻性队列研究

Characteristics and outcomes of COVID-19 in Chinese immune thrombocytopenia patients: A prospective cohort study.
PubMed 文献 · Br J Haematol · 2023-11-15

212例(18.5%)血小板计数下降,47例(4.1%)诊断为肺炎。血小板下降的危险因素包括基线血小板<50×10⁹/L、含TPO-RA的维持治疗和既往脾切除;肺炎的危险因素包括年龄≥40岁、≥2种合并症、含TPO-RA的维持治疗和免疫抑制剂。

要点

  • 基线血小板<50×10⁹/L、含TPO-RA的维持治疗和既往脾切除与血小板下降相关。
  • 年龄≥40岁、≥2种合并症、含TPO-RA的维持治疗和免疫抑制剂与肺炎相关。

核心结论

  • 本队列研究描述了既往ITP患者感染COVID-19的特征,并识别出若干与不良结局相关的因素。

研究设计与样本

  • 前瞻性队列研究,纳入全国血液病纵向队列(NICHE,NCT04645199)中感染COVID-19的既往ITP患者,感染后随访至少1个月。

主要发现

  • 212例(18.5%)患者感染后血小板计数下降。
  • 47例(4.1%)患者诊断为肺炎。
  • 血小板计数下降的危险因素:基线血小板<50×10⁹/L(OR 1.76,95%CI 1.25-2.46,p=0.001)、含TPO-RA的维持治疗(OR 2.27,95%CI 1.60-3.21,p<0.001)、既往脾切除(OR 1.98,95%CI 1.09-3.61,p=0.03)。
  • 肺炎的危险因素:年龄≥40岁(OR 2.45,95%CI 1.12-5.33,p=0.02)、≥2种合并症(OR 3.47,95%CI 1.63-7.64,p=0.001)、含TPO-RA的维持治疗(OR 2.14,95%CI 1.17-3.91,p=0.01)、免疫抑制剂(OR 3.05,95%CI 1.17-7.91,p=0.02)。

关键数值与推荐

  • 血小板计数下降定义为感染后血小板计数较基线下降。
  • 肺炎诊断依据原文未具体说明。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The coronavirus disease 2019 (COVID-19) pandemic has a significant impact on the immune system. This is the first and largest study on pre-existing immune thrombocytopenia (ITP) patients infected with COVID-19 in China. We prospectively collected ITP patients infected with COVID-19 enrolled in the National Longitudinal Cohort of Hematological Diseases (NICHE, NCT04645199) and followed up for at least 1 month after infection. One thousand and one hundred forty-eight pre-existing ITP patients were included. Two hundred and twelve (18.5%) patients showed a decrease in the platelet (PLT) count after infection. Forty-seven (4.1%) patients were diagnosed with pneumonia. Risk factors for a decrease in the PLT count included baseline PLT count <50 × 109/L (OR, 1.76; 95% CI, 1.25-2.46; p = 0.001), maintenance therapy including thrombopoietin receptor agonists (TPO-RAs) (OR, 2.27; 95% CI, 1.60-3.21; p < 0.001) and previous splenectomy (OR, 1.98; 95% CI, 1.09-3.61; p = 0.03). Risk factors for pneumonia included age ≥40 years (OR, 2.45; 95% CI, 1.12-5.33; p = 0.02), ≥2 comorbidities (OR, 3.47; 95% CI, 1.63-7.64; p = 0.001), maintenance therapy including TPO-RAs (OR, 2.14; 95% CI, 1.17-3.91; p = 0.01) and immunosuppressants (OR, 3.05; 95% CI, 1.17-7.91; p = 0.02). In this cohort study, we described the characteristics of pre-existing ITP patients infected with COVID-19 and identified several factors associated with poor outcomes.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Chen Y, Liu J, Shao S, et al. Characteristics and outcomes of COVID-19 in Chinese immune thrombocytopenia patients: A prospective cohort study. Br J Haematol. 2023. PMID: 37967471. doi:10.1111/bjh.19198

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。